Compare JPMorgan Equity Premium Income ETF (JEPI) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Eli Lilly And Co — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.76 (market cap $45.55B), while Eli Lilly And Co trades at $1,178 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 22.8× JPMorgan Equity Premium Income ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 56 Days and Eli Lilly And Co for 93 Days on average.
| JEPI | LLY | |
|---|---|---|
Market Cap | $45.55B | $1.04T |
Volume | 3,820,809 | 3,064,878 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $1.28K |
52-Week Low | $55.29 | $799.57 |
Typical Hold Time | 56 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.73, up 0.5% with a bearish technical signal from moving averages. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and July 2026. Technical indicators show neutral oscillators with key support at $56 and resistance at $57. Recent news highlights JEPI's role in income strategies and institutional interest.
The covered-call strategy provides income but may limit upside during rallies. Institutional ownership growth signals confidence, though the bearish technical outlook and income-focused strategy suggest moderate growth potential with steady dividend income as the primary appeal.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
